Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma

International Journal of Hematology

Volumn 104, Issue 2, 2016, Pages 236-244

  Makita, Shinichi ^a,b   Maruyama, Dai ^a   Maeshima, Akiko Miyagi ^a   Taniguchi, Hirokazu ^a   Miyamoto, Ken ichi ^a   Kitahara, Hideaki ^a   Fukuhara, Suguru ^a   Munakata, Wataru ^a   Kobayashi, Yukio ^a   Itami, Jun ^a   Tobinai, Kensei ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ABVd; Hodgkin lymphoma; Japanese patient

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE CORONARY SYNDROME; ACUTE TOXICITY; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BASAL CELL CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; EARLY CANCER; ESOPHAGUS CANCER; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HODGKIN DISEASE; HUMAN; JAPANESE (PEOPLE); LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHLEBITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; VERY ELDERLY; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE FREE SURVIVAL; MORTALITY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE;

EID: 84963721538     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-2007-1     Document Type: Article

References (38)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–76.
2. Connors JM. State-of-the-art therapeutics: hodgkin’s lymphoma. J Clin Oncol. 2005;23:6400–8.
3. Devita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73:881–95.
4. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol. 1986;4:1295–306.
5. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21:601–5.
6. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–84.
7. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:589–97.
8. Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50:696–702.
9. Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, et al. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin’s disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 2000;30:146–52.
10. Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, et al. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: japan Clinical Oncology Group study (JCOG 9305). Int J Hematol. 2010;92:713–24.
11. Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, et al. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705). Leuk Lymphoma. 2013;54:46–52.
12. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press 2008;322–334.
13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin’s Disease staging classification. Cancer Res. 1971;31:1860–1.
14. Hasenclever D, Diehl V, Armitage JO, Assouline D, Björkholm M, Brusamolinoet E, et al. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Eng J Med. 1998;339:1506–14.
15. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17:1244–53.
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
18. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634–42.
19. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483–9.
20. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Eng J Med. 2010;363:640–52.
21. Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomized trials. Ann Oncol. 2006;17:1749–60.
22. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428–37.
23. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206–14.
24. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21:607–14.
25. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–95.
26. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23:9198–207.
27. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365:203–12.
28. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548–54.
29. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.
30. Fludeoxyglucose F 18-PET/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma. https://clinicaltrials.gov/ct2/show/NCT00822120. Accessed October 1, 2015.
31. Non-randomized confirmatory study of interim PET-guided ABVD or ABVD/escalated BEACOPP regimen for previously untreated advanced stage Hodgkin lymphoma (JCOG1305, INNOVATE-HL study). https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000022939&language=E. Accessed November 20, 2015.
32. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21.
33. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9.
34. Eichenauer DA, Engert A. Advances in the treatment of Hodgkin lymphoma. Int J Hematol. 2012;96:535–43.
35. Younes A, Connors JM, Park SI, Fanale M, O’Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14:1348–56.
36. Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma. https://clinicaltrials.gov/ct2/show/NCT01712490. Accessed October 1, 2015.
37. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119:692–5.
38. Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126:2798–804.